Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T; MIRACL Study Investigators. Waters DD, et al. Circulation. 2002 Sep 24;106(13):1690-5. doi: 10.1161/01.cir.0000031568.40630.1c. Circulation. 2002. PMID: 12270864 Clinical Trial.
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Among authors: waters dd. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):142-7. doi: 10.1161/ATVBAHA.107.151787. Epub 2007 Nov 8. Arterioscler Thromb Vasc Biol. 2008. PMID: 17991875 Clinical Trial.
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG. Schwartz GG, et al. Among authors: waters d. Am J Cardiol. 1998 Mar 1;81(5):578-81. doi: 10.1016/s0002-9149(97)00963-6. Am J Cardiol. 1998. PMID: 9514453
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Schwartz GG, et al. Among authors: waters d. JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711. JAMA. 2001. PMID: 11277825 Clinical Trial.
Atorvastatin for acute coronary syndromes.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR. Schwartz GG, et al. Among authors: waters d. JAMA. 2001 Aug 1;286(5):533-5. JAMA. 2001. PMID: 11476650 No abstract available.
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Nicholls SJ, et al. Among authors: waters dd. Cardiovasc Drugs Ther. 2012 Feb;26(1):71-5. doi: 10.1007/s10557-011-6358-9. Cardiovasc Drugs Ther. 2012. PMID: 22109255 Clinical Trial.
RE: Praluent (Alirocumab)-Induced Renal Injury.
Rosenson RS, Larrey D, Waters DD, Olsson AG; Members of the Phase 3 Data Monitoring Committee for PRALUENT. Rosenson RS, et al. Among authors: waters dd. J Pharm Pract. 2018 Apr;31(2):138-139. doi: 10.1177/0897190017734429. Epub 2017 Oct 3. J Pharm Pract. 2018. PMID: 28974137 Free PMC article. No abstract available.
1,383 results